Listed

Outlook Therapeutics, Inc.

OTLKNasdaqCIK 1649989HealthcareFiscal year ends Sep 30

Latest reported revenue, Q4 FY2025−$91.8kRevenue, Q4 FY2025, three months to 2025-09-30−$91.8k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-12-19, accession 0001104659-25-123264. Derived: 12-month figure less the 9-month figure.Report this figureThree months to Sep 30, 2025, from the 10-K filed Dec 19, 2025.

Latest quarter: Q3 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenuenot reported (Revenue not reported)No year-earlier figure to compare
  • Gross marginnot reported (Revenue not reported)No year-earlier figure to compare
  • Operating marginnot reported (Revenue not reported)No year-earlier figure to compare
  • Net marginnot reported (Revenue not reported)No year-earlier figure to compare
  • Diluted EPS−$0.15Diluted EPS, Q3 FY2026, three months to 2026-06-30−$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-18, accession 0001104659-26-098415.Report this figure+72.7% on a year earlier
  • Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare

Last eight quarters

Full statements
Revenue−$91.8kGross margin 1098.5%
Diluted EPS−$0.15, Q3 FY2026
Outlook Therapeutics, Inc., key figures for the last eight quarters
Line itemUnitQ4 FY20242024-09-30Q1 FY20252024-12-31Q2 FY20252025-03-31Q3 FY20252025-06-30Q4 FY20252025-09-30Q1 FY20262025-12-31Q2 FY20262026-03-31Q3 FY20262026-06-30Shape over the periods
Revenue$knot reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)1,505Revenue, Q3 FY2025, three months to 2025-06-30$1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-14, accession 0001558370-25-011588.Report this figure(91.8)Revenue, Q4 FY2025, three months to 2025-09-30−$91.8k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-12-19, accession 0001104659-25-123264. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Gross margin%not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)70.8%Gross margin, Q3 FY2025, three months to 2025-06-30. gross profit / revenueGross profit: $1.1m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-18, accession 0001104659-26-098415.Revenue: $1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-14, accession 0001558370-25-011588.Report this figure1098.5%Gross margin, Q4 FY2025, three months to 2025-09-30. gross profit / revenueGross profit: −$1.0m. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-12-19, accession 0001104659-25-123264. Derived: 12-month figure less the 9-month figure.Revenue: −$91.8k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-12-19, accession 0001104659-25-123264. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Operating margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)(1046.2%)Operating margin, Q3 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$15.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-18, accession 0001104659-26-098415.Revenue: $1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-14, accession 0001558370-25-011588.Report this figure18863.9%Operating margin, Q4 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$17.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-12-19, accession 0001104659-25-123264. Derived: 12-month figure less the 9-month figure.Revenue: −$91.8k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-12-19, accession 0001104659-25-123264. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Net margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)(1338.8%)Net margin, Q3 FY2025, three months to 2025-06-30. net income / revenueNet income: −$20.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-18, accession 0001104659-26-098415.Revenue: $1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-14, accession 0001558370-25-011588.Report this figure14482.2%Net margin, Q4 FY2025, three months to 2025-09-30. net income / revenueNet income: −$13.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-12-19, accession 0001104659-25-123264. Derived: 12-month figure less the 9-month figure.Revenue: −$91.8k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-12-19, accession 0001104659-25-123264. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Diluted EPS$ per sharenot reported (Diluted EPS not reported)0.72Diluted EPS, Q1 FY2025, three months to 2024-12-31$0.72 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-17, accession 0001104659-26-016554.Report this figure(1.50)Diluted EPS, Q2 FY2025, three months to 2025-03-31−$1.50 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001104659-26-062632.Report this figure(0.55)Diluted EPS, Q3 FY2025, three months to 2025-06-30−$0.55 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-18, accession 0001104659-26-098415.Report this figurenot reported (Diluted EPS not reported)(0.38)Diluted EPS, Q1 FY2026, three months to 2025-12-31−$0.38 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-17, accession 0001104659-26-016554.Report this figure(0.05)Diluted EPS, Q2 FY2026, three months to 2026-03-31−$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001104659-26-062632.Report this figure(0.15)Diluted EPS, Q3 FY2026, three months to 2026-06-30−$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-18, accession 0001104659-26-098415.Report this figure
Free cash flow$knot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$1.4mGross margin 4.0%
Diluted EPS−$1.79, FY2025
Outlook Therapeutics, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-09-30FY20222022-09-30FY20232023-09-30FY20242024-09-30FY20252025-09-30Shape over the periods
Revenue$knot reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)1,414Revenue, FY2025, twelve months to 2025-09-30$1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-12-19, accession 0001104659-25-123264.Report this figure
Gross margin%not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)4.0%Gross margin, FY2025, twelve months to 2025-09-30. gross profit / revenueGross profit: $57.2k. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-12-19, accession 0001104659-25-123264.Revenue: $1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-12-19, accession 0001104659-25-123264.Report this figure
Operating margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)(4744.3%)Operating margin, FY2025, twelve months to 2025-09-30. operating income / revenueOperating income: −$67.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-12-19, accession 0001104659-25-123264.Revenue: $1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-12-19, accession 0001104659-25-123264.Report this figure
Net margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)(4416.2%)Net margin, FY2025, twelve months to 2025-09-30. net income / revenueNet income: −$62.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-12-19, accession 0001104659-25-123264.Revenue: $1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-12-19, accession 0001104659-25-123264.Report this figure
Diluted EPS$ per share(0.35)Diluted EPS, FY2021, twelve months to 2021-09-30−$0.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2022-12-29, accession 0001558370-22-019036.Report this figure(0.31)Diluted EPS, FY2022, twelve months to 2022-09-30−$0.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-12-22, accession 0001558370-23-020000.Report this figure(4.72)Diluted EPS, FY2023, twelve months to 2023-09-30−$4.72 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-12-27, accession 0001558370-24-016491.Report this figure(4.06)Diluted EPS, FY2024, twelve months to 2024-09-30−$4.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-12-19, accession 0001104659-25-123264.Report this figure(1.79)Diluted EPS, FY2025, twelve months to 2025-09-30−$1.79 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-12-19, accession 0001104659-25-123264.Report this figure
Free cash flow$knot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Outlook Therapeutics, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$7.0m4,376,872Added+2,409,712
PERCEPTIVE ADVISORS LLC2026-06-30$5.0m3,139,216New+3,139,216
MARSHALL WACE, LLP2026-06-30$3.2m1,987,578New+1,987,578
BlackRock, Inc.2026-06-30$2.7m1,668,579Added+1,191,108
JANE STREET GROUP, LLC2026-06-30$2.3m1,425,270New+1,425,270
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$2.0m1,245,868Added+642,262
SUSQUEHANNA INTERNATIONAL GROUP, LLP2026-06-30$1.5m968,190Added+834,106
VANGUARD FIDUCIARY TRUST CO2026-06-30$1.1m661,664Added+485,135
GILPIN WEALTH MANAGEMENT, LLC2026-06-30$882.5k555,000Reduced−45,162
SUSQUEHANNA INTERNATIONAL GROUP, LLP2026-06-30$862.1k542,200CallNew+542,200

Recent filings

All 833 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Outlook Therapeutics, Inc., recent filings
FiledFormWhat it isAccession number
2026-09-3020:30 ET8-K3.01 Delisting notice0001104659-26-112356
2026-09-1820:30 ET8-K8.01 Other events0001104659-26-108952
2026-08-2720:11 ET8-K5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0001104659-26-102446
2026-08-1821:29 ET10-QQuarterly reportPeriod 2026-06-300001104659-26-098415
2026-08-1423:54 ETSCHEDULE 13D/AOwnership report, active investor, amended0000899140-26-000895
2026-08-1412:36 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001104659-26-096510
2026-08-1412:00 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001104659-26-096478
2026-08-1220:01 ET8-K2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits0001104659-26-094848
2026-07-2421:01 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001104659-26-086685
2026-07-2423:54 ET8-K5.02 Departure or appointment of officers or directors0001104659-26-086406

Latest annual report

Form 10-K for the fiscal year ended Sep 30, 2025Filed Dec 19, 2025. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
1649989
Tickers
OTLK
Exchange
Nasdaq
SIC code
2836 Biological Products, (No Diagnostic Substances)
Sector
Healthcare
Fiscal year ends
Sep 30
Incorporated in
DE
Filer category
Non-accelerated filer<br>Smaller reporting company
Former names
Oncobiologics, Inc. (to 2018-11-13)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. Listed shows no prices and gives no investment advice.